Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities

HUO Meng; CHENG Qijian; LIN Jiayuan

doi:10.6039/j.issn.1001-0408.2025.02.15

您当前的位置：

首页 >

文章列表页 >

Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities

更新时间：2025-09-25

- Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities
- ZHONGGUO YAOFANG Vol. 36, Issue 2, Pages: 219-224(2025)
- 作者机构：
  
  1.温州医科大学附属第一医院药学部，浙江温州　325000
  2.上海交通大学医学院附属瑞金医院药学部，上海　201801
  3.上海交通大学医学院附属瑞金医院呼吸与危重症医学科，上海　201801
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.02.15
  CLC： R969.3
- Received：21 August 2024，
  
  Revised：2024-12-24，
  
  Accepted：03 January 2025，
  
  Published：30 January 2025
- 稿件说明：
移动端阅览
霍萌,程齐俭,林佳媛.1例肺血栓栓塞症伴多种合并症乳腺癌患者的抗凝治疗分析与药学监护[J].中国药房,2025,36(02):219-224.

HUO Meng,CHENG Qijian,LIN Jiayuan.Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities[J].ZHONGGUO YAOFANG,2025,36(02):219-224.
霍萌,程齐俭,林佳媛.1例肺血栓栓塞症伴多种合并症乳腺癌患者的抗凝治疗分析与药学监护[J].中国药房,2025,36(02):219-224. DOI： 10.6039/j.issn.1001-0408.2025.02.15.

HUO Meng,CHENG Qijian,LIN Jiayuan.Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities[J].ZHONGGUO YAOFANG,2025,36(02):219-224. DOI： 10.6039/j.issn.1001-0408.2025.02.15.

摘要

目的

为肺血栓栓塞症（PTE）伴多种合并症乳腺癌患者的抗凝治疗和药学监护提供参考。

方法

临床药师参与1例PTE合并继发于系统性红斑狼疮的可疑抗磷脂综合征伴血小板重度减少的乳腺癌患者的诊疗过程，并提供制订个体化抗凝方案、监测患者出血情况等药学监护。针对患者出现的PTE，临床药师建议停用所有乳腺癌治疗药物；针对初始抗凝方案，临床药师在明确血小板重度减少并非抗凝治疗的绝对禁忌证后，建议予磺达肝癸钠注射液抗凝治疗；针对长期抗凝方案和疗程，临床药师建议优选华法林，推荐疗程至少3～6个月，并根据12周后的抗磷脂抗体谱复查结果结合肿瘤治疗方案决定是否进行无限期抗凝治疗。

结果

医师采纳临床药师建议。经治疗后，患者血丝痰及气促消失，血小板恢复正常，准予带药出院。

结论

临床药师以“抗凝-出血”为切入点，通过分析乳腺癌治疗相关药物与PTE的因果关系、充分评估患者的出血和血栓复发风险、监测患者出血症状和体征及凝血指标等药学服务，为患者制定了个体化用药方案，保障了患者用药的安全有效。

Abstract

OBJECTIVE

To provide a reference for anticoagulant therapy and pharmaceutical care of the breast cancer patient with pulmonary thromboembolism （PTE） accompanied by multiple comorbidities.

METHODS

Clinical pharmacists participated in the diagnosis and treatment of a breast cancer patient with PTE accompanied by severe thrombocytopenia and suspected antiphospholipid syndrome secondary to systemic lupus erythematosus， and provided personalized pharmaceutical care as developing individualized anticoagulation plans and monitoring patient bleeding. For the occurrence of PTE， the clinical pharmacist recommended stopping all breast cancer drugs. The clinical pharmacists also cleared that severe thrombocytopenia was not the absolute contraindication for anticoagulant treatment and suggested fondaparinux sodium as the initial anticoagulation regimen. Further， warfarin was recommended as the long-term anticoagulation regimen with a recommended treatment course of at least 3-6 months by the clinical pharmacists. Whether to continue indefinite anticoagulation therapy was based on the results of the antiphospholipid antibodies after 12 weeks combined with the tumor treatment regimen.

RESULTS

The physicians adopted the advice of the clinical pharmacists. After treatment， the patient’s blood phlegm and anhelation disappeared and the platelets returned to normal. The patient was allowed to be discharged with medication.

CONCLUSIONS

Taking the “anticoagulation-bleeding” as the starting point， the clinical pharmacists develop individualized medication plans for patients so as to ensure the safety and effectiveness of medication in the patient by providing pharmaceutical care， such as analyzing the causal relationship between breast cancer treatment-related drugs and PTE， assessing the risk of bleeding and thrombus recurrence， and monitoring patients’ bleeding symptoms and signs and coagulation indicators.

关键词

Keywords

references

ZHANG Y ， CHEN Y N ， CHEN H ， et al . Performance of the Simplified Pulmonary Embolism Severity Index in predicting 30-day mortality after acute pulmonary embolism：validation from a large-scale cohort [J ] . Eur J Intern Med ， 2024 ， 124 ： 46 - 53 .

中华医学会呼吸病学分会肺栓塞与肺血管病学组，中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会，全国肺栓塞与肺血管病防治协作组 . 肺血栓栓塞症诊治与预防指南 [J ] . 中华医学杂志， 2018 ， 98 （ 14 ）： 1060 - 1087 .

Pulmonary Embolism and Pulmonary Vascular Disease Group of Respiratory Medicine Branch of Chinese Medical Association ， Working Committee on Pulmonary Embolism and Pulmonary Vascular Disease of the Respiratory Physicians Branch of the Chinese Medical Doctor Asso-ciation ， National Collaborative Group for Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular Disease . Guidelines for diagnosis，treatment and prevention of pulmonary thromboembolism [J ] . Natl Med J China ， 2018 ， 98 （ 14 ）： 1060 - 1087 .

《中国血栓性疾病防治指南》专家委员会 . 中国血栓性疾病防治指南 [J ] . 中华医学杂志， 2018 ， 98 （ 36 ）： 2861 - 2888 .

Expert Committee of Guidelines for the Prevention and Treatment of Thrombotic Diseases in China . Guidelines for prevention and treatment of thrombotic diseases in China [J ] . Natl Med J China ， 2018 ， 98 （ 36 ）： 2861 - 2888 .

王乔宇，武明芬，柳鑫，等 . 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南 [J ] . 中国临床药理学杂志， 2021 ， 37 （ 21 ）： 2999 - 3016 .

WANG Q Y ， WU M F ， LIU X ， et al . Guidelines for the selection and pharmaceutical care of anticoagulants for the prevention and treatment of venous thromboembolism in China of 2021 [J ] . Chin J Clin Pharmacol ， 2021 ， 37 （ 21 ）： 2999 - 3016 .

丁永杰，张柳，李庆云 . 肺血栓栓塞症抗凝药物应用安全性监测及对策 [J ] . 中华结核和呼吸杂志， 2024 ， 47 （ 12 ）： 1170 - 1175 .

DING Y J ， ZHANG L ， LI Q Y . Safety monitoring and countermeasures of anticoagulant drugs for pulmonary thromboembolism [J ] . Chin J Tuberc Respir Dis ， 2024 ， 47 （ 12 ）： 1170 - 1175 .

DECOUSUS H ， TAPSON V F ， BERGMANN J F ， et al . Factors at admission associated with bleeding risk in medical patients：findings from the IMPROVE investigators [J ] . Chest ， 2011 ， 139 （ 1 ）： 69 - 79 .

中华医学会心血管病学分会，中国老年学学会心脑血管病专业委员会 . 华法林抗凝治疗的中国专家共识 [J ] . 中华内科杂志， 2013 ， 52 （ 1 ）： 76 - 82 .

Chinese Society of Cardiology of Chinese Medical Association ， Committee of Cardio-Cerebral-Vascular of GSC . China expert consensus on anticoagulation therapy with warfarin [J ] . Chin J Intern Med ， 2013 ， 52 （ 1 ）： 76 - 82 .

LUTSEY P L ， ZAKAI N A . Epidemiology and prevention of venous thromboembolism [J ] . Nat Rev Cardiol ， 2023 ， 20 （ 4 ）： 248 - 262 .

LINNEMANN B ， BLANK W ， DOENST T ， et al . Diagnostics and therapy of venous thrombosis and pulmonary embolism：the revised AWMF S2k guideline [J ] . Vasa ， 2023 ， 52 （ S111 ）： 1 - 146 .

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会（CSCO）肿瘤患者静脉血栓防治指南：2024 [M ] . 北京：人民卫生出版社， 2024 ： 6 - 7 .

Guidelines Working Committee of Chinese Society of Clinical Oncology . Guidelines of Chinese Society of Clinical Oncology（CSCO）for venous thromboembolism prophylaxis and treatment guideline in patients with cancer 2024 [M ] . Beijing ： People’s Medical Publishing House ， 2024 ： 6 - 7 .

赵久良，沈海丽，柴克霞，等 . 抗磷脂综合征诊疗规范 [J ] . 中华内科杂志， 2022 ， 61 （ 9 ）： 1000 - 1007 .

ZHAO J L ， SHEN H L ， CHAI K X ， et al . Recommendations for management of antiphospholipid syndrome in China [J ] . Chin J Intern Med ， 2022 ， 61 （ 9 ）： 1000 - 1007 .

中华医学会血液学分会血栓与止血学组 . 易栓症诊断与防治中国指南：2021年版 [J ] . 中华血液学杂志， 2021 ， 42 （ 11 ）： 881 - 888 .

Thrombosis and Hemostasis Group of Hematology Branch of Chinese Medical Association . Chinese guidelines for diagnosis，prevention and treatment of thrombophilia：2021 edition [J ] . Chin J Hematol ， 2021 ， 42 （ 11 ）： 881 - 888 .

杜中英，郑兆红，魏亮，等 . 1例阿来替尼致ALK阳性NSCLC患者罕见不良反应的药学监护 [J ] . 中国药房， 2024 ， 35 （ 2 ）： 247 - 250 .

DU Z Y ， ZHENG Z H ， WEI L ， et al . Pharmaceutical care for rare ADR in a patient with ALK-positive non-small cell lung cancer induced by alectinib [J ] . China Pharm ， 2024 ， 35 （ 2 ）： 247 - 250 .

THEIN K Z ， HTUT T W ， BALL S ， et al . Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone：a systematic review and meta-analysis of randomized controlled trials [J ] . Breast Cancer Res Treat ， 2020 ， 183 （ 2 ）： 479 - 487 .

WEST M T ， SMITH C E ， KAEMPF A ， et al . CDK4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice [J ] . Eur J Haematol ， 2021 ， 106 （ 5 ）： 634 - 642 .

XU B H ， ZHANG Q Y ， ZHANG P ， et al . Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer：a randomized，phase 3 trial [J ] . Nat Med ， 2021 ， 27 （ 11 ）： 1904 - 1909 .

NIU N ， QIU F ， XU Q S ， et al . A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer [J ] . Nat Commun ， 2022 ， 13 （ 1 ）： 7043 .

国家肿瘤质控中心乳腺癌专家委员会，中国抗癌协会肿瘤药物临床研究专业委员会 . CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性乳腺癌临床应用专家共识： 2023版 [J ] . 中华肿瘤杂志， 2023 ， 45 （ 12 ）： 1003 - 1017 .

Breast Cancer Expert Committee of National Tumor Qua-lity Control Center ， Professional Committee on Clinical Research of Tumor Drugs of Chinese Anti-Cancer Association . Consensus on the clinical use of CDK4/6 inhibitors for the treatment of hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer：2023 edition [J ] . Chin J Oncol ， 2023 ， 45 （ 12 ）： 1003 - 1017 .

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology：cancer-associated venous thromboembolic disease：version 1 [EB/OL ] .（ 2024-04-25 ）[ 2024-09-18 ] . https：//www.nccn.org/professionals/physician_gls/pdf/vte.pdf https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf .

STEFFEL J ， COLLINS R ， ANTZ M ， et al . 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [J ] . Europace ， 2021 ， 23 （ 10 ）： 1612 - 1676 .

中国成人血小板减少症急诊管理共识专家组 . 中国成人血小板减少症急诊管理专家共识 [J ] . 中华急诊医学杂志， 2022 ， 31 （ 2 ）： 161 - 168 .

Expert Group on Emergency Management of Adult Thrombocytopenia in China . Expert consensus on emergency management of adult thrombocytopenia in China [J ] . Chin J Emerg Med ， 2022 ， 31 （ 2 ）： 161 - 168 .

中华医学会临床药学分会《磺达肝癸钠药学实践专家共识》编写工作组 . 磺达肝癸钠药学实践专家共识 [J ] . 医药导报， 2022 ， 41 （ 11 ）： 1571 - 1581 .

The Working Group for the Compilation of the Expert Consensus on the Pharmaceutical Practice of Chlorpromazine Sodium of Clinical Pharmacy Branch of Chinese Medical Association . Expert consensus on the pharmaceutical practice of chlorpromazine sodium [J ] . Her Med ， 2022 ， 41 （ 11 ）： 1571 - 1581 .

重庆市医院协会药事管理专业委员会 . 抗凝药物审方规则专家共识 [J ] . 中国药房， 2023 ， 34 （ 24 ）： 2951 - 2967 .

Pharmaceutical Administration Committee of Chongqing Hospital Association . Expert consensus on prescription review rules of anticoagulants [J ] . China Pharm ， 2023 ， 34 （ 24 ）： 2951 - 2967 .

COHEN H ， CUADRADO M J ， ERKAN D ， et al . 16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends [J ] . Lupus ， 2020 ， 29 （ 12 ）： 1571 - 1593 .

SAYAR Z ， BURKE S ， MITTAL P ， et al . The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome [J ] . Lupus ， 2022 ， 31 （ 12 ）： 1485 - 1490 .

TEKTONIDOU M G ， ANDREOLI L ， LIMPER M ， et al . EULAR recommendations for the management of antiphospholipid syndrome in adults [J ] . Ann Rheum Dis ， 2019 ， 78 （ 10 ）： 1296 - 1304 .

WU X L ， CAO S B ， YU B ， et al . Comparing the efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome：a systematic review and meta-analysis [J ] . Blood Coagul Fibrinolysis ， 2022 ， 33 （ 7 ）： 389 - 401 .

LIU A ， RUPANI K V ， NAYMAGON L . Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome [J ] . Eur J Haematol ， 2022 ， 109 （ 1 ）： 69 - 74 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease

Antithrombotic therapy and pharmaceutical care of a child with purpura nephritis complicated with lower extremity deep venous thrombosis

Pharmaceutical care for a patient with diabetes complicated with suspected hyperlipidemia induced by immunosuppressive agents after liver transplantation

Pharmacy practice of clinical pharmacists involved in the treatment of a case of bullous pemphigoid and pulmonary aspergillosis combined with disseminated Nocardia farcinica infection

Multimodal analgesia in the treatment of a case of pediatric primary erythromelalgia with infection and pharmaceutical care

Related Author

ZHANG Ming

YU Lu

WU Xudong

LI Boxia

LIU Weiting

CHANG Yaowen

ZHANG Chunyan

HUANG Lin

Related Institution

Dept. of Internal Medicine， Zhonggongmiao Community Hospital of Ningbo Yinzhou District No.2 Hospital Medical Community

Dept. of Clinical Pharmacy， Ningbo Yinzhou District No.2 Hospital

Dept. of Interventional Medicine， the First Hospital of Lanzhou University

Dept. of Pharmacy， the First People’s Hospital of Lanzhou

Dept. of Pharmacy， the First Hospital of Lanzhou University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰